1.Prof.Pan Jing was invited to speak at the conference,sharing the key considerations of CAR-T therapy in the treatment of acute leukemia from her own research results and time,and also focusing on the exploration of CAR-T therapy in the field of T-line tumors.2.Prof.Li Zhihui gave an oral presentation on the theme of"Maintenance Therapy with Trametinib after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with RAS Mutated Hematologic Malignancies".3.Head Nurse Wang Xiaoxia gave an oral presentation on the theme of"The Successful Treatment of Severe Oral and Nasal Ulcer with Barkin Yufu Ointment on a Relapsed AML Patient Before Secondary HSCT".

1.Oral report by Dr.Yanzhi Song"allo-HSCT improves survival outcomes in R/R B-ALL patients who are not in remission or MRD-positive after CAR-T treatment"2.Oral Report by Head Nurse Wang Xiaoxia on the Application of Multimedia Digital Platform to Carry out HSCT Pre-patient Education under the COVID-19 Epidemic3.Dr.Zhao Wing-keung presents the poster"Secondary allo-HSCT for Intensity Reduction pretreatment and Donor Replacement".4.Dr.Li Zhihui shows the poster"The good effect of allo-HSCT in the treatment of MLL gene-related hematological malignancies".5.Dr.Hui Shi presents the poster"Relapsed T-ALL after allo-HSCT treatment with Donor-derived CD7 CAR-T:Phase I Trial".6.Dr.Wang Rui shows the poster"allo-HSCT Improves Poor prognosis in MLL-AF6-positive AML patients".7.Dr.Zhanxiang Liu presents the poster"CAR-T bridging allo-HSCT achieves good results in the treatment of R/R Ph+B-ALL patients".8.Head Nurse Wang Xiaoxia showed the wall report"Nursing of a patient with AML complicated with…

1.Prof.Wu Tong gave an oral presentation on the theme of"CAR-engineered cellular therapy in hematological malignancies:A New Era!"2.Prof.Li Zhihui,Prof.Yang Fan and Head Nurse Tao Xiuyan also gave presentations.

1.Dr.Fan Yang reported the clinical results of the Venetoclax combination therapy for recurrence of acute myeloid leukemia(AML)after allogeneic hematopoietic stem cell transplantation(Allo-HSCT).The title of the report is Clinical observation on Venetoclax-based combinations for adult patients with acute myeloid leukemia relapsing after allogeneic stem cell transplantation2.Dr.Zhihui Li presented the team's exploration of the effects of genetic variants of blood and immune susceptibility genes on Allo-HSCT outcomes in patients with blood tumors.The report is entitled"Potential influence of hematological or immunological hereditary predisposition genes on outcomes of allogeneic.hematopoietic stem cell transplantation in patients with hematological malignancies3.Dr.Lin Yuehui's reported"Novel potential treatment modalities for EBF1-PDGFRB fusion gene positive B-cell precursor acute".4.Dr.Song Yanzhi reported"Busulfan/Fludarabine-based or TBI/Fludarabine-based reduced intensity co…

The transplant team presented the topic Allogeneic Hematopoietic Stem Cell Transplantation for Refractory/Relapsed B-cell Acute Lymphoblastic at the congress Preliminary research results show that the current transplantation strategy can make these refractory/relapsed B-ALL patients with little hope of cure obtain excellent treatment results,with the 6-month overall survival rate of 96.9%and disease-free survival rate of 91.7%.